LARGO, Fla., Oct. 12 /PRNewswire-FirstCall/ -- GeoPharma, Inc. today announced that Belcher Pharmaceuticals, Inc., a wholly owned subsidiary of GeoPharma, Inc., has completed the initial phase of it's multi- phase expansion plans for pharmaceutical manufacturing and R&D. The addition of this state-of-the-art 33,000 square foot facility will be utilized to further its capabilities and capacities to manufacture and distribute generic drugs.
"This is the one of many steps in our strategic expansion plans related to the manufacturing and marketing of generic pharmaceuticals," stated Mihir Taneja, CEO. "With the vast majority of blockbuster drugs coming off patent along with the many niche drug opportunities, we believe this new facility will provide us with the necessary infrastructure to allow us to produce and develop many drugs on a more aggressive basis. Furthermore, it allows us to work on a variety of drugs simultaneously without worrying about initial capacity constraints."
About GeoPharma, Inc.
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high-margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at http://www.geopharmainc.com , http://www.onlineihp.com and http://www.hoodiadexl10.com .
FORWARD-LOOKING STATEMENTS
This press release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
L.G. Zangani, LLC provides financial public relations services to the Company. As such, L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and/or other services performed for the Company. This remuneration may take the form of cash, capital stock in the Company, or warrants and/or options to purchase stock in the Company.
GeoPharma, Inc.CONTACT: Mihir Taneja of GeoPharma, Inc., +1-727-544-8866, ormihirt@onlineihp.com; or Kevin Nally of Zangani Investor Community,+1-908-788-9660 x625, or office@zangani.com
